Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Leases (2021 - 2025)

Historic Current Leases for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $3.5 million.

  • Aligos Therapeutics' Current Leases rose 457.63% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 457.63%. This contributed to the annual value of $3.4 million for FY2024, which is 597.71% up from last year.
  • Per Aligos Therapeutics' latest filing, its Current Leases stood at $3.5 million for Q3 2025, which was up 457.63% from $3.5 million recorded in Q2 2025.
  • Aligos Therapeutics' Current Leases' 5-year high stood at $3.5 million during Q3 2025, with a 5-year trough of $2.5 million in Q1 2021.
  • Over the past 5 years, Aligos Therapeutics' median Current Leases value was $3.2 million (recorded in 2023), while the average stood at $3.1 million.
  • As far as peak fluctuations go, Aligos Therapeutics' Current Leases soared by 2567.68% in 2022, and later crashed by 367.44% in 2023.
  • Over the past 5 years, Aligos Therapeutics' Current Leases (Quarter) stood at $2.8 million in 2021, then grew by 9.61% to $3.0 million in 2022, then rose by 6.39% to $3.2 million in 2023, then increased by 5.98% to $3.4 million in 2024, then increased by 3.51% to $3.5 million in 2025.
  • Its Current Leases stands at $3.5 million for Q3 2025, versus $3.5 million for Q2 2025 and $3.4 million for Q1 2025.